Human Immunodeficiency Virus type-1 (HIV-1) establishes a latent viral reservoir soon after infection, which poses a major challenge for drug treatment and curative strategies. Many efforts are therefore focused on blocking infection. To this end, both viral and host factors relevant to the onset of infection need to be considered. Given that HIV-1 is most often transmitted mucosally, strategies designed to protect against infection need to be effective at mucosal portals of entry. These strategies need to contend also with cell-free and cell-associated transmitted/founder (T/F) virus forms; both can initiate and establish infection. This review will discuss how insight from the current model of HIV-1 mucosal transmission and cell entry has highlighted challenges in developing effective strategies to prevent infection. First, we examine key viral and host factors that play a role in transmission and infection. We then discuss preventive strategies based on antibody-mediated protection, with emphasis on targeting T/F viruses and mucosal immunity. Lastly, we review treatment strategies targeting viral entry, with focus on the most clinically advanced entry inhibitors.
Oligomannose-type glycans on HIV-1 gp120 form a patch that is targeted by several broadly neutralizing antibodies (bnAbs) and that therefore is of interest to vaccine design. However, attempts to elicit similar oligomannose-specific bnAbs by immunizing with oligomannosidic glycoconjugates have only been modestly successful so far. A common assumption is that eliciting oligomannose-specific bnAbs is hindered by B cell tolerance, resulting from the presented oligomannosides being sensed as self molecules. Here, we present data, along with existing scientific evidence, supporting an additional, or perhaps alternate, explanation: serum mannosidase trimming of the presented oligomannosides in vivo. Mannosidase trimming lessens the likelihood of eliciting antibodies with capacity to bind full-sized oligomannose, which typifies the binding mode of existing bnAbs to the oligomannose patch. The rapidity of the observed trimming suggests the need for immunization strategies and/or synthetic glycosides that readily avoid or resist mannosidase trimming upon immunization and can overcome possible tolerance restrictions.
Oligomannose-type glycans on HIV-1 gp120 form a patch that is targeted by several broadly neutralizing antibodies (bnAbs) and that therefore is of interest to vaccine design. However, attempts to elicit similar oligomannose-specific bnAbs by immunizing with oligomannosidic glycoconjugates have only been modestly successful so far. A common assumption is that eliciting oligomannose-specific bnAbs is hindered by B cell tolerance, resulting from the presented oligomannosides being sensed as self molecules. Here, we present data, along with existing scientific evidence, supporting an additional, or perhaps alternate, explanation: serum mannosidase trimming of the presented oligomannosides in vivo . Mannosidase trimming lessens the likelihood of eliciting antibodies with capacity to bind full-sized oligomannose, which typifies the binding mode of existing bnAbs to the oligomannose patch. The rapidity of the observed trimming suggests the need for immunization strategies and/or synthetic glycosides that readily avoid or resist mannosidase trimming upon immunization and can overcome possible tolerance restrictions.
<!----> <!----> Oligomannosides are common constituents of plant, invertebrate, and vertebrate N-glycoproteins such as in high mannose-, hybrid-, paucimannosidic-, and complex-type glycans but also occur as antigenic determinants in the viral glycan shield of HIV 1. 1–3 Furthermore, α-mannosides are frequently found components of bacterial and fungal polysaccharides. 4–5 Glycosylation reactions leading to α-mannosides are well developed, but there is still a need to improve the assembly of oligomannosides with respect to scalability, ease of purification, and simplification of protecting group patterns. 6 <!----> <!---->
<!----> <!----> Nitro sugars are considered important synthetic intermediates in glycochemistry. 1 Nitro alcohols 2a and 2b have been recently used as key starting materials for the synthesis of carbopeptoids and their triazole isosters. 2 Diastereoisomeric mixture 2a,b can be easily dehydrated by the use of Moffatt protocol and the obtained α,β-unsaturated nitromethylene derivative is susceptible to Michael additions with various nucleophiles. 3 Combination of the latter sequence with isoxazole formation in a 1,3-dipolar cycloaddition reaction opens possibilities for the synthesis of various synthetic glycoconjugates. 4 Title compound 2a and its isomer 2b have been used also 142as starting materials in the synthesis of triazolyl carbohydrates. 5 Nevertheless, on many occasions pure isomer 2a is required. Thus, Liu and coworkers have reported a chiral pool-based multistep synthesis of (3S,4S)-3-((R)-1,2-dihydroxyethyl)pyrrolidine-3,4-diol from compound 2a. 6 Also a practical access to carbohydrate-based spiro-oxazolidinones starting from nitromethyl furanose 2a has been developed. 7 Furthermore, nitro alcohol 2a could be easily converted into (thio)urea organocatalysts which were studied for Friedel–Crafts alkylation of indoles with β-nitrostyrenes. 8 <!----> <!---->